Effect of CPAP vs. MADs on blood pressure reduction
Original question
What does the literature say about the effect of CPAP vs. MAAs/MADs for reduction in blood pressure?
Summary
- Both CPAP and mandibular advancement devices/appliances (MADs/MAAs) produce modest average reductions in blood pressure (BP) in patients with obstructive sleep apnea (OSA), typically in the low–single‑digit mm Hg range.
- A 2015 network meta‑analysis found no statistically significant difference between CPAP and MADs in their effect on systolic or diastolic BP, despite greater AHI reduction with CPAP.[1]
- A more recent RCT in high‑CV‑risk hypertensive OSA patients (CRESCENT) showed noninferiority of MAD vs CPAP for 24‑h ambulatory BP at 6 months, with numerically greater BP lowering in the MAD arm, driven by better adherence.[2]
- Current guidelines (AASM/AADSM) acknowledge limited BP data but conclude that MADs may be as effective as CPAP for BP reduction in selected patients, and BP effects should not by themselves dictate choice of therapy.[3]
Key Comparative Evidence
1. 2015 Network Meta‑analysis: CPAP vs MAD for BP
- Bratton et al., JAMA 2015, network meta‑analysis of RCTs comparing CPAP, MADs, and inactive control in OSA, focusing on BP.[1]
- Both CPAP and MADs were associated with modest reductions in BP vs control.
- Direct comparison (CPAP vs MAD):
- Interpretation:
- In aggregate RCT data, no meaningful difference in BP reduction between CPAP and MAD, despite CPAP being superior for AHI and oxygenation.
- Supports the concept that real‑world BP impact is driven by adherence and nightly exposure, not just physiologic efficacy.
2. CRESCENT Trial (2024): MAD Noninferior to CPAP for 24‑h BP
- CRESCENT (Cardiosleep Research Program…; NCT04119999), randomized, open‑label, noninferiority trial in adults ≥40 with hypertension, increased CV risk, and moderate‑to‑severe OSA (AHI ≥15/h).[2]
- n=220 randomized 1:1 to MAD vs CPAP; primary outcome: change in 24‑h mean arterial BP at 6 months.
- Results:
- MAD group: 24‑h mean arterial BP decreased by 2.5 mm Hg from baseline (P=0.003).[2]
- CPAP group: no significant change in 24‑h mean arterial BP (P=0.374).[2]
- Between‑group difference: –1.6 mm Hg (95% CI –3.51 to 0.24); met prespecified noninferiority margin of 1.5 mm Hg (P<0.001 for noninferiority).[2]
- Interpretation:
- MAD was noninferior to CPAP for BP lowering and may be modestly better numerically, although the superiority signal is small and CIs include no difference.
- The effect size is modest but clinically relevant at the population level; in resistant or high‑risk hypertension, even 2–3 mm Hg reductions in mean BP can matter, though individual impact is variable.
3. Guideline and Consensus Statements
- 2015 AASM/AADSM Clinical Practice Guideline for Oral Appliance Therapy for OSA:[3]
- Acknowledges more robust BP evidence for CPAP than for oral appliances, and notes that no RCTs have assessed hard CV outcomes with oral appliances.
- States that, based on the limited available data, oral appliances may be as effective as CPAP in at least some patient populations for lowering BP, and this should not preclude their use.[3]
- AASM + AADSM joint guideline summary also emphasizes:
Mechanistic and Practical Considerations
Magnitude of BP Reduction
- Both CPAP and MADs generally yield small average BP reductions (often ~2–3 mm Hg in 24‑h mean or nighttime BP in RCTs and meta‑analyses).[1][2]
- Effects tend to be more pronounced in:
- Patients with uncontrolled or resistant hypertension at baseline.
- Those with more severe OSA or greater nocturnal BP surges.
- The modest magnitude suggests these devices are adjuncts, not substitutes, for antihypertensive therapy.
Adherence vs Physiologic Efficacy
- CPAP: Greater reduction in AHI and desaturation, but often poorer adherence over the long term.
- MADs: Less potent reduction in AHI, but typically higher nightly use and long‑term tolerance.[4][3]
- Net BP effect in practice appears similar, consistent with the Bratton meta‑analysis and CRESCENT.[1][2]
Clinical Implications for Choice of CPAP vs MAD
-
If the primary goal is BP reduction in a hypertensive OSA patient
-
Patients intolerant of CPAP
-
Resistant hypertension / high CV risk
- CRESCENT suggests that in hypertensive patients with increased CV risk, MAD provides noninferior ambulatory BP reduction vs CPAP over 6 months.[2]
- For these patients, prioritizing the modality they will use consistently is reasonable, while continuing to optimize pharmacologic antihypertensive therapy.
-
Hard CV Outcomes
- For CPAP, trials in secondary prevention (e.g., SAVE) have not shown clear reductions in major CV events despite modest BP effects, especially with suboptimal adherence.
- For MADs, there are no RCT data on CV events; current evidence is limited to intermediate outcomes like BP and AHI.[3]
- Therefore, no therapy can currently be preferred on the basis of CV outcome data alone; decisions should be individualized.
Bottom Line
- CPAP and MADs both lead to modest reductions in BP in OSA, with no robust evidence that CPAP is superior to MAD for BP lowering. Network meta‑analysis and the recent CRESCENT RCT support equivalence or noninferiority of MADs to CPAP for ambulatory BP outcomes.[1][2]
- Given similar BP effects but differences in tolerability and AHI control, therapy choice should prioritize OSA severity, patient‑specific anatomy, and adherence, with BP considered an important but secondary factor.
Sources
- https://pubmed.ncbi.nlm.nih.gov/26624827/
- https://pubmed.ncbi.nlm.nih.gov/38588926/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC4481062/
- https://aasm.org/aasm-and-aadsm-issue-new-joint-clinical-practice-guideline-for-oral-appliance-therapy/
- https://sleepmedres.org/journal/view.php?doi=10.17241%2Fsmr.2023.01921
- https://www.lovemysleep.ca/single-post/mandibular-advancement-vs-cpap-for-blood-pressure-reduction-in-patients-with-obstructive-sleep-apnea
AI-generated answer based on the cited sources. Check the sources before applying it.